Press release

Herantis Pharma Plc | Press Release | August 13, 2024 at 12:00:00 EEST

Herantis Pharma: Invitation to 1H 2024 report webinar on August 22, 2024

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease will webcast the 1H 2024 results, Thursday August 22 at 10:00 am EEST (9:00 CEST). The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&A session.

Herantis will release 1H 2024 Report on August 22 at 8:00 am EEST (7:00 CEST). The report and presentation materials will be made available online at www.herantis.com.

Please use the following link to register for this event:
https://herantis.videosync.fi/2024-h1-results

After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.

Following the webcast of the live call, a recording will be available on Herantis Pharma’s website: https://herantis.com/news-events/video-presentations/

For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

Certified Advisor:

UB Corporate Finance Ltd

Tel: +358 9 25 380 225

Email: ubcf@unitedbankers.fi

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com